Search results
Results from the WOW.Com Content Network
The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another ...
Many health plans no longer cover the drug, which went off patent in 2019, and there are other options for patients on the market, Novo said. Patients push back against Novo Nordisk move to scrap ...
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year. ($1 = 0.9172 euros)
Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls. Terfenadine (Seldane, Triludan) 1997–1998 France, South Africa, Oman, others, US Prolonged QT interval; ventricular tachycardia [2] [3]
Insulin detemir was approved for medical use in the European Union in June 2004, and in the United States in June 2005. [5] [6] [8] It is on the World Health Organization's List of Essential Medicines. [9] In 2022, it was the 127th most commonly prescribed medication in the United States, with more than 4 million prescriptions. [10] [11]
A category for drugs withdrawn from the market after marketing commenced for any reason (voluntarily or involuntarily). For drug candidates that were abandoned prior to being marketed due to side effects, lack of efficacy, superior competitors, or other reasons, see Category:Abandoned drugs
The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year. Drugmakers to raise US prices on over 250 medicines starting ...
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).